Skip to content

Comparative Study on the Clinical Efficacy of Acetazolamide and Methazolamide in Acute Mountain Sickness

Comparative Study on the Clinical Efficacy of Methazolamide and Acetazolamide in the Prevention of Acute Mountain Sickness

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089203
Enrollment
Unknown
Registered
2024-09-03
Start date
2024-09-08
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute mountain sickness

Interventions

Acetazolamide Intervention Group:Take 500 mg of acetazolamide daily (250 mg each time, twice a day) for 1-3 days. On the 4th day, travel to Litang by car. Continue taking acetazolamide for days 4-6.
Methazolamide Intervention Group:Take 200 mg of methazolamide daily (100 mg each time, twice a day) for 1-3 days. On the 4th day, travel to Litang by car. Continue taking methazolamide for days 4-6.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Never been to an altitude above 2,500 meters 2) Han ethnicity 3) Age between 18 and 60 years (inclusive) 4) Previously healthy individuals with no history of chronic diseases, surgeries, or mental disorders; non-smokers (or those who have not smoked more than 400 cigarette-years, e.g., 20 cigarettes per day for 20 years) and no history of alcohol abuse or other bad habits 5) Normal blood pressure (systolic pressure <140 mmHg; diastolic pressure <90 mmHg) 6) No cardiovascular or pulmonary diseases and not taking any chronic medications 7) Normal levels of blood glucose, blood lipids, complete blood count, and liver and kidney function tests

Exclusion criteria

Exclusion criteria: 1) Presence of contraindications for carbonic anhydrase inhibitors 2) Obesity (body mass index =30 kg/m²) 3) Cardiovascular and respiratory diseases 4) Pregnant women

Design outcomes

Primary

MeasureTime frame
Is acute mountain sickness occurring;Is high-altitude pulmonary edema occurring;Respiratory sleep monitoring;Adverse drug event;

Secondary

MeasureTime frame
6 minute walk experiment;blood routine examination;blood biochemistry;Vital signs;Exhaled nitric oxide levels;

Countries

CHINA

Contacts

Public ContactLuo Fengming

West China Hospital, Sichuan University

fengmingluo@outlook.com+86 189 8060 1355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026